Thermo Fisher Scientific, AbbVie, and Vera Therapeutics are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that research, develop and commercialize medical products, therapies and technologies based on biological processes, genetics and cellular engineering. Their value is heavily influenced by scientific breakthroughs, clinical‐trial outcomes and regulatory approvals, making them more volatile and higher‐risk than many other equities. Investors in biotech stocks aim for outsized returns from successful drug development but must contend with long, costly and uncertain paths to market. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of TMO stock traded up $6.86 during trading on Friday, hitting $405.22. The company had a trading volume of 729,877 shares, compared to its average volume of 1,897,861. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The stock's 50-day moving average is $422.35 and its two-hundred day moving average is $496.67. The stock has a market capitalization of $152.97 billion, a price-to-earnings ratio of 24.56, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78. Thermo Fisher Scientific has a 52 week low of $390.50 and a 52 week high of $627.88.
Read Our Latest Research Report on TMO
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
NYSE ABBV traded up $2.82 on Friday, reaching $190.29. 1,014,650 shares of the company's stock traded hands, compared to its average volume of 6,217,132. AbbVie has a 12 month low of $163.52 and a 12 month high of $218.66. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. The stock has a 50-day simple moving average of $184.56 and a 200 day simple moving average of $186.80. The stock has a market cap of $336.12 billion, a PE ratio of 79.28, a P/E/G ratio of 1.62 and a beta of 0.56.
Read Our Latest Research Report on ABBV
Vera Therapeutics (VERA)
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
NASDAQ VERA traded down $8.87 on Friday, reaching $21.76. 7,634,048 shares of the company's stock traded hands, compared to its average volume of 905,981. Vera Therapeutics has a 12 month low of $18.53 and a 12 month high of $51.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The stock has a 50-day simple moving average of $22.39 and a 200 day simple moving average of $31.76. The stock has a market cap of $1.39 billion, a PE ratio of -8.38 and a beta of 1.13.
Read Our Latest Research Report on VERA
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
